Skip to main content

Table 1 Patient characteristics

From: Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma

Characteristic

No. of patients

%

Patients evaluable

40

100

Age, years

  

   Median

65

 

   Range

34–75

 

Sex

  

   Male

24

60

   Female

16

40

ECOG PS

  

   0

6

15

   1

27

67.5

   2

7

17.5

Disease location

  

   Gastric

30

75

   GEJ

10

25

Histologic type

  

   Diffuse

19

47.5

   Intestinal

15

37.5

   Unspecified

6

15

Previous adjuvant chemotherapy

6

15

Status of primary tumor

  

   Unresected

28

70

   Resected

12

30

Predominant site of disease

  

   Liver

24

60

   Peritoneum

8

20

   Nodes

4

10

   Lung

2

5

   Bone

2

5

No. of metastatic sites

  

   1

11

27.5

   2

19

47.5

   ≥ 3

10

25

  1. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status;
  2. GEJ, gastroesophageal junction